111 Capital
Source: SEC Form 13F · as of Mar 2026111 Capital holds 21 biotech & pharma companies tracked by BioSniper, totaling $40.7M in value as of Mar 2026 (SEC Form 13F).
Companies held
21
Total value held
$40.7M
| Company | Shares | Value |
|---|---|---|
| AZNASTRAZENECA PLC | 93,536 | $18.2M |
| GILDGILEAD SCIENCES, INC. | 19,705 | $2.7M |
| LLYELI LILLY & Co | 2,786 | $2.6M |
| AMGNAMGEN INC | 7,110 | $2.5M |
| PMPhilip Morris International Inc | 10,211 | $1.7M |
| VRTXVERTEX PHARMACEUTICALS INC / MA | 3,740 | $1.7M |
| ABBVAbbVie Inc. | 7,504 | $1.6M |
| UNHUnitedHealth Group Incorporated Common Stock (DE) | 5,834 | $1.6M |
| ABTABBOTT LABORATORIES | 14,335 | $1.5M |
| JNJJOHNSON & JOHNSON | 5,937 | $1.5M |
| CORCencora Inc. | 2,795 | $878K |
| GEHCGE HealthCare Technologies Inc. | 10,587 | $754K |
| REGNREGENERON PHARMACEUTICALS, INC. | 929 | $718K |
| GMOptec International, Inc. | 8,911 | $664K |
| MCKMcKesson Corporation | 711 | $615K |
| BMRNBIOMARIN PHARMACEUTICAL INC | 5,430 | $307K |
| IDXXIDEXX LABORATORIES INC /DE | 536 | $301K |
| ELVElevance Health Inc. | 898 | $263K |
| VTRSViatris Inc | 19,219 | $260K |
| DVADaVita Inc. | 1,669 | $257K |
| ALNYALNYLAM PHARMACEUTICALS, INC. | 666 | $220K |
13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.